Alimera’s Alaway Follows Novartis’ Zaditor To Spring 2007 OTC Launch
This article was originally published in The Tan Sheet
Executive Summary
Alimera Sciences plans to launch its Alaway over-the-counter ophthalmic solution at the same time as its bioequivalent competitor, Novartis' Zaditor.
You may also be interested in...
B&L buys Alaway
Alimera Sciences and Bausch & Lomb announce Dec. 20 B&L has purchased Alimera's OTC allergy franchise, including recently-approved Alaway, for an undisclosed amount. "The acquisition of Alaway not only enhances our current OTC product portfolio by giving us a stronger and longer-lasting product to address the needs of consumers who suffer itchy eyes, but it also gives us an excellent technology platform for the development of product line extensions in the ocular allergy category," B&L Corporate VP and Global Pharmaceutical Category Leader Gary M. Phillips, M.D., says. Alimera Sciences announced FDA's approval of Alaway Dec. 5 (1"The Tan Sheet" Dec. 11, 2006, p. 7)...
Novartis Expects Clear Demand For Zaditor Following OTC Switch Approval
Novartis plans to differentiate its antihistamine eye-drop product Zaditor in the OTC market by positioning the drug as a treatment for the cause, not the symptoms, of itchy eyes
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers